Athenex, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
ABBVAbbVie, Inc. 0.07%90.101.9%$1168.51m
JNJJohnson & Johnson -0.41%146.370.7%$1047.46m
BMYBristol-Myers Squibb Co. -0.13%59.741.0%$978.99m
MRKMerck & Co., Inc. -0.22%78.870.7%$821.61m
PFEPfizer Inc. -0.86%37.850.9%$817.24m
LLYEli Lilly & Co. 0.51%151.421.1%$454.36m
AZNAstraZeneca Plc 0.11%53.561.2%$264.87m
NVSNovartis AG 0.54%86.750.2%$155.39m
GSKGlaxoSmithKline Plc -0.31%41.410.2%$138.62m
NVONovo Nordisk A/S -0.45%64.670.1%$88.50m
SNYSanofi -0.38%48.500.2%$75.00m
RGENRepligen Corp. 0.98%130.477.1%$68.12m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 1.57%58.710.0%$44.36m
TPTXTurning Point Therapeutics, Inc. -3.77%65.990.0%$37.31m
ARCTArcturus Therapeutics Holdings, Inc. -0.49%36.560.0%$35.47m

Company Profile

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.